+34 679 490 537info@nanbiosis.com

Posts Taged cutting-edge-biomedical-solutions

NANBIOSIS participation in CPhI Worldwide

NANBIOSIS has participated in the most important event of the pharmaceutical industry, CPhI Worldwide, the largest fair held in Spain. More than 45,000 professionals from more than 150 countries of the main companies in the sector and more than 2,500 companies meet at IFEMA (Madrid) from 9 to 11 October.

One of the novelties to be taken into account in this edition of the CPhI Worldwide will be the presentation of biological products by the bioLIVE platform, highlighting the recent growth of biological medicines.

BioLIVE, adjacent to CPhI Worldwide in 2018, is the exhibition and conference for large molecule biopharma needs. The event focuses specifically on manufacturing and processing and provides a unique platform connecting biotechs, big pharma and service providers across the value chain. The collaboration with CPhI Worldwide, brings together the small and large molecule worlds, creating a unique platform for both industries to learn from each other.

The arrival of this great event in Madrid comes at a particularly good time for the pharmaceutical industry in Spain, classified by global companies as one of the most internationally recognized, according to the Annual Report of CPhI, Global Pharma Index. This places Spain in the fourth place on the world scale (behind the United States, Germany and Japan and at the level of France and Italy) for the quality of its pharmaceutical production and the knowledge of its professionals. This study also points to Spain as the fastest-growing country worldwide in terms of innovation, for its ability to develop innovative manufacturing methods and new medicines.

NANBIOSIS has taken advantage of this incomparable framework to publicize its Cutting-Edge Biomedical Solutions and hold bilateral meetings with companies, including present collaborators such as Qualicaps  (in the picture, Jesús Izco Executive Director of NANBIOSIS and Laura Canalejas together with Susana Ecenarro, Scientific Business Development Manager and Scientific Business Development Director of Qualicaps respectively)

Qualicaps supplies pharmaceutical-grade capsules together with a comprehensive service along the drug product life cycle through Qualicaps global team of commercial, scientific and technical experts. Originated in 1897 within Eli Lilly & Co. as a capsule manufacturing plant in the company’s headquarters in Indianapolis, USA. It is currently integrated into the Japanese group Mitsubishi Chemical Holdings Corporation. 

 

Read More

NANBIOSIS develops on demand projects and cutting edge biomedical solutions.

In this video, Jesús Izco Ex. Director of NANBIOSIS, presents NANBIOSIS as one of the 29 ICTS that currently make up the national ICTS map. It consist consists of 27 units grouped into five platforms  which ofer their services under a single contact point and develops on demand projects and cutting edge biomedical solutions in different biomedical applications such as biosensors, live image, contrast agents, therapeutic agents, regenerative medicine, drug delivery, among others.

 

 

Read More

NANBIOSIS Youtube channel: new video-presentations and informative capsules about NANBIOSIS activity

NANBIOSIS makes available its youtube channel with informative videos about the ICTS-NANBIOSIS and the activity of some of its research units and platforms, as well as its Cutting-edge Biomedical Solutions and Nanomedicines Cascade Characterizations

NANBIOSIS youtube

Read More

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the first groups/companies meeting organized by Nanbiosis, in which about 70 B2B meetings  were held.

The meeting brought together about 40 participants from 14 research groups (from the CIBER-BBN and the CCMIJU) and 10 companies, which discussed the latest advances in the research lines developed by the groups and platforms of Nanbiosis and on the needs and demands of the industry in smart biomaterials and devices for targeted drug delivery and regenerative medicine.

Jesus Izco, Coordinator of Nanbiosis, presented the new Cutting-Edge Biomedical Solutions“, soon available on the ICTS website. These are integrated solutions to advanced challenges in nanomedicine, biomaterials, medical device, and diagnostic that can be developed by several units under a  one-stop shop model, optimized with the experience and scientific and technical knowledge of the research groups of excellence that manage the involved units. Some of the Cutting-edge biomedical solutions presented in the meeting were preclinical validation of biomaterials, mechanical and surface characterization, biocompatibility and studies of biofilm formation and infections.

The CIBER-BBN prsentations were: “Instructive materials for regenerative medicine” by Miguel Ángel Mateos (NANBIOSIS U5 IP: Elisabeth Engel); “Molecular biomaterials for drug delivery and biomedical applications” byNathaly Veronica Segovia (NANBIOSIS U6 / IP Jaume Veciana and Nora Ventosa); “Advances with micro-nano technologies for in vitro devices and point of care” by Rosa Villa (NANBIOSIS U8 ); “Development of new dosage forms for advanced therapies based on new biomaterials” by José Luis Pedraz (NANBIOSIS U10); “Contact lenses functionalized for the prevention of corneal infections” by Jordi Esquena (NANBIOSIS U12 / IP Carlos Rodríguez); “Combined in-silico and in-vitro models of the cell microenvironment and drug delivery effects in cancer and tissue engineering applications” by Fany Peña (NANBIOSIS U13 / IP Miguel Á. Martínez); “Surface of the biomaterial: the first contact with our body” by  Marisa González (NANBIOSIS U16 ); “Use of biomaterials for the repair of soft tissue defects” by Bárbara Pérez Khöler (NANBIOSIS U17 / IP J M. Bellón and Gemma Pascual); “Controlled release systems based on mesoporous materials with molecular doors for applications in therapy and diagnosis” by Ramón Martínez Máñez (NANBIOSIS U26); “New intelligent devices and biomaterials for the treatment of pathologies of the retina and the nervous system” (Eduardo Fernández); and “Near-infrared responsive scaffolds for biomedical applications” (Nuria Vilaboa).

On the part of the CCMJU, the presentations were the following: “Application of Mesenchymal Stem Cells in preclinical models for surgical and cardiovascular research” by Javier García Casado (NANBIOSIS U14); “Regenerative medicine in animal models of cutaneous healing and diabetic models” by Beatriz Moreno (NANBIOSIS U19); “Preclinical studies of biomaterials” by Idoia Díaz-Güemes (NANBIOSIS U21 /IP: FM Sánchez Margallo); “Porcine model of myocardial infarction as a translational research platform in regenerative medicine” by Verónica Crisóstomo (NANBIOSIS U24).

In the turn of the companies, they presented some collaboration opportunities AJL, i-Vascular, Praxis Pharmaceutical, Technical Proteins Nanobiotechnology and REGEMAT 3D; and they also participated in the Rovi, Viscofan, Biomag and Biogelx Laboratories forum.

These meetings, where links are established between research groups and companies, address issues of business and scientific interest, allowing direct contacts between researchers and business managers.

Read More